The CJC-1295 and ipamorelin pairing has a mechanistic rationale, but the recorded clinical searches do not establish combination benefit or safety. The individual reports concern different routes and populations. Neither ingredient is FDA-approved; current 503A records do not establish routine bulk-compounding eligibility [12].
Two peptides, two growth-hormone signals
Your pituitary can respond to more than one growth-hormone signal, including GHRH from the hypothalamus and stimulation through the ghrelin receptor. CJC-1295 works on the first. Ipamorelin works on the second. That provides a mechanistic rationale, not evidence of a clinically useful combination effect.
The two also behave very differently in time. One dose of CJC-1295 with DAC kept growth hormone raised for six days or more [3]. Ipamorelin, given by infusion to healthy men, produced a single burst of growth hormone that peaked at about 40 minutes and then faded, with a half-life of about 2 hours [5].
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Type | Lab-made GHRH analog (peptide) | Lab-made ghrelin mimic, a growth-hormone secretagogue (peptide) |
| FDA-approved? | No, never | No, never |
| FDA advisers' vote on compounding | Against all five forms, December 4, 2024: 0-13-0 for four, 1-12-0 for the acetate [8] | Against both forms, October 29, 2024: 0-12-1 each [10] |
| Where FDA lists it today | In no 503A category; in FDA's table of substances whose nominations were withdrawn [11] | In no 503A category; still in Category 2 of FDA's 503B list (outsourcing facilities) [13] |
| People studied | FDA’s 63 reported healthy adults, most given a single dose; one phase 2 trial stopped early and never published [7] | Healthy-volunteer dosing studies plus one phase 2 trial in 114 surgery patients [5] [6] |
| Half-life in people | 5.8 to 8.1 days (the DAC form) [3] | About 2 hours [5] |
| Most reported side effects | Injection-site reactions (about 70%), headache, flushing, raised heart rate [7] | In the surgery trial, overall side-effect rates similar to placebo (87.5% vs 94.8%); FDA flagged two deaths of unclear cause [6] [9] |
| Sport (WADA) | Prohibited at all times, S2.2.4 [14] | Prohibited at all times, S2.2.4 [14] |
Status as of this update, from FDA's briefing documents, meeting records and compounding lists.
What CJC-1295 did in healthy adults
One injection of CJC-1295 with DAC raised growth hormone 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults [3]. Those were two small randomized, placebo-controlled trials in people aged 21 to 61. After repeated doses, IGF-1 stayed above baseline for up to 28 days.
A second study in healthy young men asked whether that steady push flattens the body's natural rhythm. It didn't. Growth hormone still came in pulses, and the pulses kept their size and frequency. What changed was the floor between pulses: trough growth hormone rose 7.5-fold, mean growth hormone rose 46% and IGF-1 rose 45% one week after a single dose [4].
The reviewed reports do not establish a clinical muscle, fat-loss, sleep, recovery or anti-aging benefit. FDA’s 2024 review summarizes 63 healthy-adult exposures,87% men and 73% single-dose. The 2009 protein-analysis report used 11 men drawn from the Ionescu cohort, so publication counts should not be interpreted as independent cohorts [7].
What ipamorelin did: a short burst, and a failed patient trial
In healthy men given ipamorelin by infusion, growth hormone rose in a single episode at every dose tested, then fell back to negligible levels [5]. The drug cleared quickly, with a terminal half-life of about 2 hours.
Ipamorelin's one controlled patient trial tested it for slow gut recovery after bowel surgery. Among 114 patients, the median time to a first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant (p = 0.15) [6]. The authors found no significant difference on any efficacy measure. More on the molecule itself is on our ipamorelin page.
No combination trial was identified in the recorded searches
The recorded literature and registry searches did not identify a clinical trial administering CJC-1295 with ipamorelin. Two plausible mechanisms do not establish synergy, a reliable hormone response or a clinical benefit from the combination. FDA’s review quotes a seller’s fold-increase claim without clinical outcome evidence [9].
That gap matters for safety as well as benefit. Two drugs that both raise growth hormone could add up, and the side effects of each, such as flushing and a faster heart rate with CJC-1295, were measured only one at a time. For what is known about harms, see whether CJC-1295 and ipamorelin are safe.
DAC or no DAC: they are different molecules
The CJC-1295 in the published trials carried DAC, a chemical add-on that binds the peptide to albumin in the blood and stretches its half-life to about 6 to 8 days [3] [4]. The "no-DAC" product often sold as CJC-1295, or as mod GRF 1-29, is a different molecule. FDA treats them as two distinct active moieties [7]. In FDA's ipamorelin review, a specialist interviewed for an FDA-funded report described a "trending" combination of ipamorelin with CJC-1295, and FDA's note identifies that CJC-1295 as the version without DAC [9].
FDA also found the naming itself unreliable. Its review counted at least five distinct CJC-1295 substances sold or studied under at least nine names. FDA warned that this is a safety risk, because a patient "may be dosed with a different bulk drug substance than the physician ordered" [7]. In practice this means human data on CJC-1295 with DAC tell you nothing direct about a no-DAC vial, and a label may not say which one it is.
| CJC-1295 with DAC | CJC-1295 without DAC (mod GRF 1-29) | |
|---|---|---|
| What FDA calls it | CJC-1295 DAC (free base), plus acetate and trifluoroacetate salts | CJC-1295 (free base), plus an acetate salt |
| Human studies | Yes: the published healthy-volunteer trials [3] [4] | None that FDA identified [7] |
| Half-life in people | 5.8 to 8.1 days [3] | Not measured in people |
| FDA advisers' vote | Against, 0-13-0 for each form [8] | Against: 0-13-0 (free base), 1-12-0 (acetate) [8] |
Safety signals FDA reported
The most common side effect of CJC-1295 in the published studies was an injection-site reaction, in about 70% of people in the first Teichman study. Headache occurred in 63% on CJC-1295 against 14% on placebo. Flushing appeared only in people given the drug, and it was dose-dependent: 40% after the lower dose and 100% after the higher one [7]. Heart rate rose with dose in the Ionescu study.
FDA's briefing also describes a phase 2 trial in people with HIV-related lipodystrophy that was stopped after a participant died of a heart attack. FDA's account comes from internet news reports of the time. The treating physician's most likely explanation was undiagnosed coronary artery disease, and the trial data were never published [7].
For ipamorelin, FDA's review of the surgery trial reported serious adverse events in 17.9% of ipamorelin patients and 15.5% on placebo, and two deaths in the ipamorelin group after anastomotic leaks. FDA wrote that it is unclear whether those deaths were related to ipamorelin [9]. A fuller safety review sits on our CJC-1295 and ipamorelin safety page.
FDA status: never approved, and two votes against compounding
Neither CJC-1295 nor ipamorelin has ever been FDA-approved. Neither is on the 503A bulks list, the list of ingredients a pharmacy may use to compound a drug when there is no approved product or USP monograph [12]. FDA's compounding advisory committee voted against adding them, by the margins below.
| Substance | Meeting | Vote | Source |
|---|---|---|---|
| Ipamorelin (free base) | October 29, 2024 | 0 / 12 / 1 | Meeting transcript [10] |
| Ipamorelin acetate | October 29, 2024 | 0 / 12 / 1 | Meeting transcript [10] |
| CJC-1295 (free base) | December 4, 2024 | 0 / 13 / 0 | Summary minutes [8] |
| CJC-1295 acetate | December 4, 2024 | 1 / 12 / 0 | Summary minutes [8] |
| CJC-1295 DAC (free base) | December 4, 2024 | 0 / 13 / 0 | Summary minutes [8] |
| CJC-1295 DAC acetate | December 4, 2024 | 0 / 13 / 0 | Summary minutes [8] |
| CJC-1295 DAC trifluoroacetate | December 4, 2024 | 0 / 13 / 0 | Summary minutes [8] |
A "yes" vote meant placing the substance on the 503A bulks list. FDA had proposed not listing any of them. The December 2024 minutes were approved on February 21, 2025.
Withdrawal of a nomination does not create a compounding exemption or drug approval. The current FDA entries and reviewed primary materials do not establish an ordinary 503A bulk-compounding basis for either ingredient. Investigational authorization follows a separate framework; the BPC-157 guide explains the same distinction.
Why FDA recommended against both
FDA's reviewers gave overlapping reasons for both peptides. The short version: the substances are hard to pin down chemically, the human safety record is small and short, and approved treatments already exist for the conditions they were nominated for.
- Identity and purity. FDA judged the CJC-1295 forms not well characterized, partly because of the naming confusion, and flagged possible immunogenicity and peptide-related impurities for injected peptides [7] [11].
- Short, small studies. CJC-1295 was nominated for growth hormone deficiency, a long-term condition, but its long-term safety in people is unknown and there are no safety data in children [7].
- Unclear deaths and lab changes. For ipamorelin, FDA pointed to the two deaths in the surgery trial and to higher rates of low potassium and high blood sugar in the ipamorelin group [9].
- Approved alternatives. FDA noted that approved therapies exist for growth hormone deficiency, and compounded products lack an FDA-approved label establishing the product-specific risks such as flushing, a faster heart rate or dizziness [7].
A committee vote is advice, not a rule. In both cases the vote matched what FDA staff had proposed, so the advice and the agency's position point the same way. FDA has not added either peptide to the bulks list since.
In sport: prohibited at all times
WADA's Prohibited List names both. Section S2.2.4, growth hormone releasing factors, lists CJC-1295 among the GHRH analogs and ipamorelin among the growth hormone secretagogues, prohibited in and out of competition [14]. Sermorelin and tesamorelin sit in the same section.
Commercial access and authorized research are separate questions
There is no FDA-approved product containing either peptide, and a US pharmacy cannot compound either one under section 503A. That leaves no established routine pharmacy-compounding route; investigational access has separate requirements. Products labeled "research use only" are not meant for people, and the label alone does not establish the identity or quality of the contents.
If your interest is low growth hormone, the question to bring to a prescriber is whether you have growth hormone deficiency, and which approved treatments fit if you do. For comparison, sermorelin is a GHRH fragment that was once FDA-approved and is still compounded, and tesamorelin is an approved brand-only drug for one narrow use. How we weigh evidence and status is set out on how we check.
- Do my symptoms and labs point to growth hormone deficiency, and how would you test for it?
- Which FDA-approved treatments would fit my situation?
- If you suggest a compounded product, which pharmacy makes it, and is the ingredient one it may legally use?
Terms used on this page
- DAC (drug affinity complex): a chemical add-on that makes a peptide bind albumin in the blood, associated with the long half-life of the studied DAC form.
- GHRH analog: a lab-made copy of growth-hormone-releasing hormone, the hypothalamus signal that tells the pituitary to release growth hormone.
- Ghrelin mimetic (secretagogue): a compound that acts on the ghrelin receptor and triggers growth hormone release.
- PCAC: FDA's Pharmacy Compounding Advisory Committee. Its votes advise FDA; they don't decide.
- 503A bulks list: the list of ingredients a state-licensed pharmacy may compound from when there is no USP monograph and no approved drug containing it.
A current observational registry, NCT07717866, lists 52 actual participants in a multimodal veterans program and names ipamorelin among several physiological-supplementation options. It has no posted results and does not isolate ipamorelin, establish its route-specific safety or test this CJC combination [15].
Sackmann-Sala’s 2009 serum-protein report used 11 healthy men from an earlier CJC cohort. It measured candidate protein biomarkers, not muscle growth, fat loss or functional recovery [16]. Counting that publication as a new independent trial would overstate the evidence.